The challenge of developing a vaccine against hepatitis C virus

Journal of Hepatology

Volumn 37, Issue 5, 2002, Pages 684-695

  Forns, Xavier ^a   Bukh, Jens ^b   Purcell, Robert H ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HEPATITIS C VACCINE; PEPTIDE; RECOMBINANT PROTEIN; HEPATITIS VACCINE;

ANIMAL MODEL; CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; GENETIC HETEROGENEITY; HEPATITIS C VIRUS; IMMUNITY; IMMUNOGENICITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VACCINATION; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS STRAIN; ANIMAL; GENETICS; HEPATITIS C; HUMAN; IMMUNOLOGY;

ANIMALS; HEPACIVIRUS; HEPATITIS C; HUMANS; VIRAL HEPATITIS VACCINES;

EID: 0036844816     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00308-2     Document Type: Review

References (115)

1. Rice CM. In: Fields BN, Knippe DM, Howley PM, editors. Fields Virology, Lippnicot-Raven: Philadelphia, 1996. pp. 931-960.
2. Bukh J, Apgar CL, Yanagi M. Toward a surrogate model for hepatitis C virus: An infectious molecular clone of the GB virus-B hepatitis agent. Virology 1999;262:470-478.
3. Simons JN, Leary TP, Dawson GJ, Pilot-Matias TJ, Muerhoff AS, Schlauder GG, et al. Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1995;1:564-569.
4. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.
5. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999;107:2S-9S.
6. Houghton M. The hepatitis C viruses. In: Fields BN, Knippe DM, Howley PM, editors. Fields Virology, Lippnicot-Raven: Philadelphia, 1996. pp. 1035-1058.
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-965.
8. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
9. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432.
10. Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999;31(Suppl. 1):17-24.
11. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994;343:388-390.
12. Bukh J, Thimme R, Forns X, Chang KM, Yanagi M, Emerson SU, et al. Acute resolving monoclonal hepatitis C virus (HCV) infection in a chimpanzee modifies subsequent infections with the homologous monoclonal virus. Hepatology (Abstract) 1999;30:452A.
13. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-140.
14. Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspe G. Immunity in hepatitis C infection. J Infect Dis 1992;165:438443.
15. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
16. Forns X, Purcell RH, Bukh J. Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol 1999;7:402-410.
17. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: Quasispecies nature of HCV genome distribution. J Virol 1992;66:3225-3229.
18. Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992;89:3468-3472.
19. Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci 1995;92:2755-2759.
20. Sitia G, Cella D, De Mitri MS, Novati R, Foppa CU, Perackis K, et al. Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission. J Med Virol 2001;64:476-481.
21. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001;15:883-895.
22. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996;93:15394-15399.
23. Bukh J, Thimme R, Saterfield W, Forns X, Chang K, Yanagi M, et al. Sterilizing immunity against hepatitis C virus is subtype specific, is apparently not mediated by neutralization antibodies, but is correlated with anamnestic cellular immune responses. Hepatology (Abstract) 2001;34:253A.
24. Barouch DH, Kunstmann J, Kuroda M, Schmitz J, Santra S, Peyerl F, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002;415:335-339.
25. Major ME, Mihalik K, Fernandez J, Seidman J, Kleiner D, Kolykhalov AA, et al. Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol 1999;73:3317-3325.
26. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001;15:883-895.
27. Kolykhalov AA, Agapov E, Blight KJ, Mihalik K, Feinstone S, Rice CM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997;277:570-574.
28. Yanagi M, Purcell R, Emerson SU, Bukh J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci USA 1997;94:8738-8743.
29. Yanagi M, St Claire M, Shapiro M, Emerson SU, Purcell RH, Bukh J. Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology 1998;244:161-172.
30. Yanagi M, Purcell RH, Emerson SU, Bukh J. Hepatitis C virus: An infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology 1999;262:250-263.
31. Forns X, Thimme R, Govindarajan S, Emerson SU, Purcell RH, Chisari FV, et al. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci USA 2000;97:13318-13323.
32. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000;288:339-344.
33. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997;158:1473-1481.
34. Rehermann B, Chang KM, McHutchinson J, Kokka R, Houghton M, Rice CM, et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996;70:7092-7102.
35. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: Hypervariable region 1 as a decoy. J Virol 1999;73:2938-2946.
36. Gale Jr MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the non-structural 5A protein. Virology 1997;230:217-227.
37. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999;285:107-110.
38. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994;91:7792-7796.
39. Yu MW, Shen L, Major ME, Feinstone SM, Jong JS. Protective antibodies in immune globulins prepared from anti-hepatitis C virus-positive plasma units: update of a chimpanzee study. In: Margolis HS, Alter MJ, Liang TJ, Dienstag JL, editors. Viral Hepatitis and Liver Disease (Proceedings of the 2000 International Symposium on Viral Hepatitis and Liver Disease), International Medical Press: Atlanta, Georgia, 2002. pp. 374-377.
40. Krawczynski K, Fattom A, Culver D, Kamili S, Spelbring J, Basham I, et al. Passive transfer of anti-HCV in chronic and acute HCV infection in chimpanzees - Trials of experimental immune treatment. Hepatology (Abstract) 1999;30:423A.
41. Feray C, Gigou M, Samuel D, Ducot B, Maisonneuve P, Reynes M, et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998;128:810-816.
42. Zibert A, Meisel H, Kraas W, Schulz A, Jung G, Roggendorf M. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 1997;25:1245-1249.
43. Allander T, Beyene A, Jacobson SH, Grillner L, Persson MA. Patients infected with the same hepatitis C virus strain display different kinetics of the isolate-specific antibody response. J Infect Dis 1997;175:26-31.
44. Bjoro K, Skaug K, Haaland T, Froland SS. Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. QJM 1999;92:433-441.
45. Lechmann M, Liang TJ. Vaccine development for hepatitis C. Semin Liver Dis 2000;20:211-226.
46. Abrignani S, Houghton M, Hsu HH. Perspectives for a vaccine against hepatitis C virus. J Hepatol 1999;31(Suppl. 31):259-263.
47. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-1406.
48. Wong DK, Dudley DD, Afdhal NH, Dienstag J, Rice CM, Wang L, et al. Liver-derived CTL in hepatitis C virus infection: Breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 1998;160:1479-1488.
49. Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992;149:3339-3344.
50. Chang KM, Gruener NH, Southwood S, Sidney J, Pape GR, Chisari FV, et al. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol 1999;162:1156-1164.
51. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996;98:706-714.
52. Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmaz D, Weiner AJ, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993;104:580-587.
53. Ferrari C, Valli A, Galati L, Penna A, Scaccaglia P, Giuberti T, et al. T-cell response to structural and non-structural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994;19:286-295.
54. Lechmann M, Ihlenfeldt HG, Braunschweiger I, Giers G, Jung G, Matz B, et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 1996;24:790-795.
55. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 1995;346:1006-1007.
56. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6:578-582.
57. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10:439-449.
58. Thimme R, Bukh J, Chang KM, Pemberton J, Purcell RH, Chisari FV. HCV persists despite a multispecific peripheral and intrahepatic T cell response in acutely infected chimpanzees. Hepatology (Abstract) 1999;30:422A.
59. Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 2001;33:1479-1487.
60. Weiner AJ, Paliard X, Selby MJ, Medina-Selby A, Coit D, Nguyen S, et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol 2001;75:7142-7148.
61. Major ME, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice CM, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol 2002;76:6586-6595.
62. Nakajima N, Hijikata M, Yoshikura H, Shimizu YK. Characterization of long-term cultures of hepatitis C virus. J Virol 1996;70:3325-3329.
63. Bartenschlager R, Lohmann V. Novel cell culture systems for the hepatitis C virus. Antiviral Res 2001;52:1-17.
64. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 1996;93:1759-1763.
65. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-941.
66. Dimmock NJ. Neutralization of animal viruses. Curr Top Microbiol Immunol 1993;183:1-149.
67. Takikawa S, Ishii K, Aizaki H, Suzuki T, Asakura H, Matsuura Y, et al. Cell fusion activity of hepatitis C virus envelope proteins. J Virol 2000;74:5066-5074.
68. Letvin NL, Barouch DH, Montefiori DC. Prospects for vaccine protection against hiv-1 infection and AIDS. Annu Rev Immunol 2002;20:73-99.
69. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-113.
70. Pietschmann T, Lohmann V, Kaul A, Krieger N, Rinck G, Rutter G, et al. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 2002;76:4008-4021.
71. Yanagi M, St Claire M, Emerson SU, Purcell RH, Bukh J. In vivo analysis of the 3′ untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci USA 1999;96:2291-2295.
72. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994;91:1294-1298.
73. Houghton M, Choo QL, Chien D, Kuo G, Weiner A, Coates S, et al. Development of an HCV vaccine. In: Turin MM, et al., editors. Viral Hepatitis and Liver Disease, Minerva Medica: Turin, 1997. pp. 656659.
74. Houghton M, Choo QL, Kuo G, Weiner A, Chien D, Ralston R, et al. Prospects for prophylactic and therapeutic hepatitis C virus vaccines. Princess Takamatsu Symp 1995;25:237-243.
75. Depla E, Priem S, Verschoor E, Roskams T, Desmet V, Fuller S, et al. Therapeutic vaccination of chronically infected chimpanzees with the HCV E1 protein. Hepatology (Abstract) 1999;30:408A.
76. Leroux-Roels G, Depla E, Hulstaert F, De Smet J, Desombere J, Maertens G. A candidate therapeutic vaccine for chronic hepatitis C infection based on envelope 1 protein: tolerability and immunogenicity in healthy adult volunteers. Proceedings of the 8th International Symposium on Hepatitis C and Related Viruses. Paris, 2001. pp. 85.
77. Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into virus like particles in insect cells. J Virol 1998;72:3827-3836.
78. Baumert TF, Vergalla J, Satoi J, Thomson M, Lechmann M, Herion D, et al. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology 1999;117:1397-1407
79. Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 2001;34:417-423.
80. Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus like particles induce virus-specific humoral and cellular immunity and protect against recombinant hepatitis C virus-vaccinia infection in mice. Proceedings of the 8th International Symposium on Hepatitis C Virus and Related Viruses. Paris 2001. pp. 76.
81. Tighe H, Corr M, Roman M, Raz E. Gene vaccination: Plasmid DNA is more than just a blueprint. Immunol Today 1998;19:89-97.
82. Forns X, Emerson SU, Tobin GJ, Mushahwar IK, Purcell RH, Bukh J. DNA immunization of mice and macaques with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine 1999;17:1992-2002.
83. Saito T, Sherman GJ, Kurokohchi K, Guo ZP, Donets M, Yu MY, et al. Plasmid DNA-based immunization for hepatitis C virus structural proteins: Immune responses in mice. Gastroenterology 1997;112:1321-1330.
84. Nakano I, Maertens G, Major ME, Vitvitski L, Dubuisson J, Fournillier A, et al. Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol 1997;71:7101-7109.
85. Fournillier A, Nakano I, Vitvitski L, Depla E, Vidalin O, Maertens G, et al. Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes. Hepatology 1998;28:237-244.
86. Lee SW, Cho JH, Lee KJ, Sung YC. Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses. Mol Cells 1998;8:444-451.
87. Fournillier A, Depla E, Karayiannis P, Vidalin O, Maertens G, Trepo C, et al. Expression of non-covalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol 1999;73:7497-7504.
88. Forns X, Allander T, Rohwer-Nutter P, Bukh J. Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface. Virology 2000;274:75-85.
89. Lee SW, Cho JH, Sung YC. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene. J Virol 1998;72:8430-8486.
90. Inchauspe G. DNA vaccine strategies for hepatitis C. J Hepatol 1999;30:339-346.
91. Forns X, Payette PJ, Ma X, Satterfield W, Eder G, Mushahwar IK, et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 2000;32:618-625.
92. Fournillier A, Wychowski C, Boucreux D, Baumert TF, Meunier JC, Jacobs D, et al. Induction of hepatitis C virus envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol 2001;75:12088-12097.
93. Lasarte JJ, Corrales FJ, Casares N, Lopez-Diaz DC, Qian C, Xie X, et al. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: The role of nitric oxide. J Immunol 1999;162:5270-5277.
94. Inchauspe G, Vitvitski L, Major ME, Jung G, Spengler U, Maisonnas M, et al. Plasmid DNA expressing a secreted or non-secreted form of hepatitis C virus nucleocapsid: Comparative studies of antibody and T-helper responses following genetic immunization. DNA Cell Biol 1997;16:182-195.
95. Lai MM. Hepatitis viruses and signal transduction: True to the core? Hepatology 2000;32:427-429.
96. Encke J, Zu PJ, Geissler M, Wands JR. Genetic immunization generates cellular and humoral immune responses against the non-structural proteins of the hepatitis C virus in a murine model. J Immunol 1998;161:4917-4923.
97. Cho JH, Lee SW, Sung YC. Enhanced cellular immunity to hepatitis C virus non-structural proteins by codelivery of granulocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization. Vaccine 1999;17:1136-1144.
98. Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997;158:1231-1237.
99. Krieg AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 2001;3:15-24.
100. Ma X, Forns X, Gutierrez R, Mushahwar IK, Wu T, Payette P, et al. DNA-based vaccination against hepatitis C virus (HCV): Effect of expressing different forms of HCV E2 protein and use of CpG-optimzed vectors in mice. Vaccine 2002;20:3263-3271.
101. Sjolander A, Cox J. Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines. Adv Drug Deliv Rev 1998;34:321-338.
102. Polakos NK, Drane D, Cox J, Ng KW, Selby MJ, Chien D, et al. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a non-classical ISCOM vaccine. J Immunol 2001;166:3589-3598.
103. Makimura M, Miyake S, Akino N, Takamori K, Matsuura Y, Miyamura T, et al. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine 1996;14:28-36.
104. Large MK, Kittlesen DJ, Hahn YS. Suppression of host immune response by the core protein of hepatitis C virus: Possible implications for hepatitis C virus persistence. J Immunol 1999;162:931-938.
105. Paoletti E, Taylor J, Meignier B, Meric C, Tartaglia J. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC. Dev Biol Stand 1995;84:159-163.
106. Moss B, Carroll MW, Wyatt LS, Bennink JR, Hirsch VM, Goldstein S, et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 1996;397:7-13.
107. Frolov I, Hoffman TA, Pragai BM, Dryga SA, Huang HV, Schlesinger S, et al. Alphavirus-based expression vectors: strategies and applications. Proc Natl Acad Sci USA 1996;93:11371-11377.
108. Brinster C, Chen M, Boucreux D, Paranhos-Baccala G, Liljestrom P, Lemmonier F, et al. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J Gen Virol 2002;83:369-381.
109. Pancholi P, Liu Q, Tricoche N, Zhang P, Perkus M, Prince AM. DNA prime canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and non-structural proteins. J Infect Dis 2000;182:18-27.
110. Buonocuore L, Blight KJ, Rice CM, Rose J. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol 2002;76:6865-6872.
111. Shata MT, Stevceva L, Agwale S, Lewis GK, Hone DM. Recent advances with recombinant bacterial vaccine vectors. Mol Med Today 2000;6:66-71.
112. Wedemeyer H, Gagneten S, Davis A, Bartenschlager R, Feinstone S, Rehermann B. Oral immunization with HCV-NS3-transformed Salmonella: Induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology 2001;121:1158-1166.
113. Esumi M, Rikihisa T, Nishimura S, Goto J, Mizuno K, Zhou YH, et al. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees. Arch Virol 1999;144:973-980.
114. Puntoriero G, Meola A, Lahm A, Zucchelli S, Ercole BB, Tafi R, et al. Towards a solution for hepatitis C virus hypervariability: Mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J 1998;17:3521-3533.
115. Cerino A, Meola A, Segagni L, Furione M, Marciano S, Triyatni M, et al. Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles. J Immunol 2001;167:3878-3886.